Effects of Pravastatin and Ursodeoxycholic Acid on Cholesterol and Bile Acid Metabolism in Patients with Cholesterol Gallstones

Overview

Journal J Gastroenterol

Specialty Gastroenterology

Date 1994 Feb 1

PMID 8199696

Citations 5

Authors

S Okamoto

K Nakano

K Kosahara

M Kishinaka

H Oda

H Ichimiya

K Chijiiwa

S Kuroki

Affiliations

Soon will be listed here.

Abstract

To investigate the effects of pravastatin and ursodeoxycholic acid (UDCA) on cholesterol and bile acid metabolism in humans, 41 patients with cholesterol gallstone disease were allocated to four groups and treated with pravastatin (20 mg/day), UDCA (600 mg/day), both pravastatin and UDCA, or neither drug (control) for 1-2 weeks prior to elective cholecystectomy. Cholesterol 7 alpha-hydroxylase activity and serum levels of total 7 alpha-hydroxycholesterol were significantly increased by pravastatin and unaffected by UDCA. 3-Hydroxy-3-methylglutaryl coenzyme A reductase activity was markedly increased by pravastatin and decreased by UDCA. UDCA significantly decreased biliary cholesterol concentration and the cholesterol saturation index and prolonged the nucleation time; however, pravastatin alone had little effect on biliary lithogenicity. Serum total and low-density lipoprotein (LDL)-cholesterol levels were reduced most by the combined administration of pravastatin and UDCA. In conclusion, at a dose of 20 mg/day, pravastatin increased bile acid synthesis but did not decrease biliary lithogenicity. UDCA had no significant effect on bile acid synthesis, but markedly decreased biliary lithogenicity.

Citing Articles

Grading operative findings at laparoscopic cholecystectomy- a new scoring system.

Sugrue M, Sahebally S, Ansaloni L, Zielinski M World J Emerg Surg. 2015; 10:14.

PMID: 25870652 PMC: 4394404. DOI: 10.1186/s13017-015-0005-x.

Atorvastatin induces bile acid-synthetic enzyme Cyp7a1 by suppressing FXR signaling in both liver and intestine in mice.

Fu Z, Cui J, Klaassen C J Lipid Res. 2014; 55(12):2576-86.

PMID: 25278499 PMC: 4242450. DOI: 10.1194/jlr.M053124.

Dissolution of gallstones with simvastatin, an HMG CoA reductase inhibitor.

Chapman B, Burt M, Chisholm R, Allan R, Yeo K, Ross A Dig Dis Sci. 1998; 43(2):349-53.

PMID: 9512129 DOI: 10.1023/a:1018862507469.

Short-term effects of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor on cholesterol and bile acid synthesis in humans.

Yoshida T, Honda A, Shoda J, Abei M, Matsuzaki Y, Tanaka N Lipids. 1997; 32(8):873-8.

PMID: 9270980 DOI: 10.1007/s11745-997-0112-2.

Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors.

Desager J, Horsmans Y Clin Pharmacokinet. 1996; 31(5):348-71.

PMID: 9118584 DOI: 10.2165/00003088-199631050-00003.

References

FRIEDEWALD W, Levy R, Fredrickson D . Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972; 18(6):499-502. View

Hirota I, Chijiiwa K, Noshiro H, Nakayama F . Effect of chenodeoxycholate and ursodeoxycholate on nucleation time in human gallbladder bile. Gastroenterology. 1992; 102(5):1668-74. DOI: 10.1016/0016-5085(92)91728-m. View

Bjorkhem I . Effects of mevinolin in rat liver: evidence for a lack of coupling between synthesis of hydroxymethylglutaryl-CoA reductase and cholesterol 7 alpha-hydroxylase activity. Biochim Biophys Acta. 1986; 877(1):43-9. DOI: 10.1016/0005-2760(86)90116-5. View

Hardison W, Grundy S . Effect of ursodeoxycholate and its taurine conjugate on bile acid synthesis and cholesterol absorption. Gastroenterology. 1984; 87(1):130-5. View

Stone B, Evans C, Prigge W, DUANE W, GEBHARD R . Lovastatin treatment inhibits sterol synthesis and induces HMG-CoA reductase activity in mononuclear leukocytes of normal subjects. J Lipid Res. 1989; 30(12):1943-52. View

Horiuchi I, Ohya T, Tazuma S, Mizuno T, Takizawa I, Kajiyama G . Effects of pravastatin (CS-514) on biliary lipid metabolism in patients with hyperlipidemia. Metabolism. 1991; 40(3):226-30. DOI: 10.1016/0026-0495(91)90101-2. View

Hoeg J, BREWER Jr H . 3-Hydroxy-3-methylglutaryl--coenzyme A reductase inhibitors in the treatment of hypercholesterolemia. JAMA. 1987; 258(24):3532-6. View

Yanagisawa J, Itoh M, Ishibashi M, Miyazaki H, Nakayama F . Microanalysis of bile acid in human liver tissue by selected ion monitoring. Anal Biochem. 1980; 104(1):75-86. DOI: 10.1016/0003-2697(80)90279-1. View

Goldberg I, Holleran S, Ramakrishnan R, Adams M, Palmer R, Dell R . Lack of effect of lovastatin therapy on the parameters of whole-body cholesterol metabolism. J Clin Invest. 1990; 86(3):801-8. PMC: 296795. DOI: 10.1172/JCI114777. View

10.

Gollish S, Burnstein M, Ilson R, Petrunka C, Strasberg S . Nucleation of cholesterol monohydrate crystals from hepatic and gall-bladder bile of patients with cholesterol gall stones. Gut. 1983; 24(9):836-44. PMC: 1420078. DOI: 10.1136/gut.24.9.836. View

11.

Tsujita Y, Kuroda M, Tanzawa K, Kitano N, Endo A . Hypolipidemic effects in dogs of ML-236B, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Atherosclerosis. 1979; 32(3):307-13. DOI: 10.1016/0021-9150(79)90174-6. View

12.

Noma A, Okabe H, Ueno Y, Shinohara H . Improved method for simultaneous determination of cholesterol in high- and low-density lipoproteins. Clin Chem. 1979; 25(8):1480-1. View

13.

BARTLETT G . Phosphorus assay in column chromatography. J Biol Chem. 1959; 234(3):466-8. View

14.

. Therapeutic response to lovastatin (mevinolin) in nonfamilial hypercholesterolemia. A multicenter study. The Lovastatin Study Group II. JAMA. 1986; 256(20):2829-34. DOI: 10.1001/jama.1986.03380200067023. View

15.

Brown M, Goldstein J . A receptor-mediated pathway for cholesterol homeostasis. Science. 1986; 232(4746):34-47. DOI: 10.1126/science.3513311. View

16.

Mashige F, Imai K, Osuga T . A simple and sensitive assay of total serum bile acids. Clin Chim Acta. 1976; 70(1):79-86. DOI: 10.1016/0009-8981(76)90007-3. View

17.

Mitchell J, LOGAN G, Stone B, DUANE W . Effects of lovastatin on biliary lipid secretion and bile acid metabolism in humans. J Lipid Res. 1991; 32(1):71-8. View

18.

Nilsell K, Angelin B, Leijd B, Einarsson K . Comparative effects of ursodeoxycholic acid and chenodeoxycholic acid on bile acid kinetics and biliary lipid secretion in humans. Evidence for different modes of action on bile acid synthesis. Gastroenterology. 1983; 85(6):1248-56. View

19.

Reihner E, Rudling M, Stahlberg D, Berglund L, Ewerth S, Bjorkhem I . Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol. N Engl J Med. 1990; 323(4):224-8. DOI: 10.1056/NEJM199007263230403. View

20.

Reihner E, Angelin B, Rudling M, Ewerth S, Bjorkhem I, Einarsson K . Regulation of hepatic cholesterol metabolism in humans: stimulatory effects of cholestyramine on HMG-CoA reductase activity and low density lipoprotein receptor expression in gallstone patients. J Lipid Res. 1990; 31(12):2219-26. View